Targeted Technology Funds — Full Portfolio
24 tracked investments · listed companies and verified rows first
Smith+Nephew is a medical technology company that develops products for the repair, regeneration, and replacement of soft and hard tissue, serving orthopedic and sports medicine patients.
HealthtechMedical DevicesLondon, GB
PartnerAlan Dean· solo GP
Maker of the Spline-Fix External Fixator System for treating a range of bone fractures.
PartnerAlan Dean· solo GP
Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.
HealthtechMedical DevicesMountain View, US
Matt Brokaw(CEO & President)Derrick Sung(Executive Officer)Matthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)Andre Cheng(Executive Officer)Fred Dinger(Executive Officer, Director)
PartnerAlan Dean· solo GP
Medical device maker developing the Angel Catheter to prevent pulmonary embolism in critically ill patients; acquired by Mermaid Medical Group in 2018.
PartnerAlan Dean· solo GP
PartnerAlan Dean· solo GP
Provides technologies for detection, neutralization, and removal of endotoxin for bioresearch and bioprocess markets.
PartnerAlan Dean· solo GP
Developing the Surfacer Inside-Out Access Catheter System, a novel approach to central venous access.
PartnerAlan Dean· solo GP
Bluegrass Vascular develops the Surfacer Inside-Out Access Catheter System, a medical device using an "Inside-Out" approach to restore and preserve central venous access in patients with chronically occluded veins such as the superior vena cava.
HealthtechMedical Devices
John Gurley(Developer of the Inside-Out approach; Department of Cardiology, University of Kentucky)
PartnerAlan Dean· solo GP
Medical technology company focused on tissue regeneration and repair using proprietary scaffold materials.
PartnerAlan Dean· solo GP
Provides high-throughput, high-accuracy automated cellular patch clamp testing instruments for drug development research.
PartnerAlan Dean· solo GP
BiotechSan Antonio, US
James R. Garvin(Chief Executive Officer, President, Secretary and Treasurer)
PartnerAlan Dean· solo GP
Designs and manufactures instruments and devices for sinus surgery; acquired by Smith & Nephew in 2013.
PartnerAlan Dean· solo GP
HealthtechSan Antonio, US
David Schneider(Executive Officer, Director)Maggie Pemberton(Executive Officer)
BoardPaul Castella(Executive Officer, Director)Jim Traa(Director)John Pinsent(Director)Joe Brennan(Director)
PartnerAlan Dean· solo GP
Medical device company providing the neoClose Trocar Port Closure System for laparoscopic and minimally invasive surgery.
PartnerAlan Dean· solo GP
Oxnard, US
Vito SAN FILIPPO(Executive Officer)MARIANNE THERESA CRONIN(Executive Officer, Director)
PartnerAlan Dean· solo GP
Enhances drug discovery by optimizing protein solubility and stability; acquired by InventaBioTech in 2016.
PartnerAlan Dean· solo GP
PartnerAlan Dean· solo GP
StemBioSys develops cell culture technology, including the patented CELLvo Matrix that replicates the body's physiological microenvironment to expand mesenchymal stem cells and specialty cells while preserving their stem-like properties.
BiotechHealthtechLongevityMedical DevicesSan Antonio, US
Jean Cheever(Director)Chen Xiao-Dong(Director)Mark D Horsey(Executive Officer)Robert Hutchens(Director)John W Feik(Director)Steven Davis(Co-founder)
PartnerAlan Dean· solo GP
Xenex builds pulsed Xenon UV light disinfection robots that deactivate pathogens missed during manual cleaning, used by hospitals to reduce environmental contamination and healthcare-associated infections.
HealthtechMedical DevicesRobotics
Mark (Tuck) Stibich(Co-founder)Julie Stachowiak(Co-founder)Morris Miller(Co-founder & CEO)Mark "Tuck" Stibich(Founder & Chief Scientific Officer)
PartnerAlan Dean· solo GP
World leader in UV room disinfection robot systems for healthcare facilities.
PartnerAlan Dean· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.